precision cell immunotherapy + cisplatin + 5-fluorouracil

This therapy is a **combination of precision cell immunotherapy, cisplatin, and 5-fluorouracil**. Precision cell immunotherapy refers to tailored use of immune cells (often T cells or other engineered immune cells) designed to specifically recognize and attack cancer cells based on the patient's individual tumor characteristics[1][3][5][7]. Cisplatin and 5-fluorouracil are chemotherapeutic agents; **cisplatin** is a platinum-based drug that cross-links DNA, leading to apoptosis, while **5-fluorouracil** is a pyrimidine analog that inhibits DNA synthesis by blocking thymidylate synthase[3][5]. The combination aims to leverage the tumor-targeting power of immunotherapy with the cytotoxic effects of conventional chemotherapy[5]. This multi-modal approach is most commonly investigated in oncology, especially in solid tumors such as head and neck, esophageal, and other epithelial cancers.